Conference Coverage

VIDEO: Case for rivaroxaban & aspirin for PAD gets stronger

Publish date: March 21, 2018

 

REPORTING FROM ACC 18

COMPASS was sponsored by Bayer, the company that along with Janssen markets rivaroxaban. Dr. Anand has been a consultant to Bayer and Novartis. Dr. Beckman has been a consultant to Janssen and other pharmaceutical companies.

SOURCE: Anand SS et al. J Amer Coll Cardiol. 2018 Mar 11. doi: 10.1016/j.jacc.2018.03.008.

Pages

Recommended Reading

'This has to change': Surgeon pain, disability on the rise
MDedge Cardiology
VIDEO: Retinal infarctions get missed as stroke harbingers
MDedge Cardiology
Embracing Life’s Simple 7 slashes PAD risk
MDedge Cardiology
On-label stent use looks safe in intracranial atherosclerotic disease
MDedge Cardiology
Promising outcomes of thrombolysis for caval extension of iliofemoral DVT
MDedge Cardiology
Large-vessel vasculitis: More severe in HIV-infected patients
MDedge Cardiology
VIDEO: Stroke benefits from stem cells maintained for 2 years
MDedge Cardiology
JAK inhibitors for RA: Is VTE risk overblown?
MDedge Cardiology
Viremic suppression linked to decreased MACE rate in patients with HCV-cirrhosis
MDedge Cardiology
Thrombectomy’s success treating strokes prompts rethinking of selection criteria
MDedge Cardiology